KURAMOCHI HIDEKAZU
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Associate Professor
Article types Original article
Language English
Peer review Non peer reviewed
Title Long-term Results of a Phase II Study of Neoadjuvant SOX for Advanced Gastric Cancer
Journal Formal name：Anticancer research
Abbreviation：Anticancer Res
ISSN code：17917530/02507005
Domestic / ForeginForegin
Volume, Issue, Page 44(1),pp.195-204
Author and coauthor ITO Shunichi†, KURAMOCHI HIDEKAZU*, SERIZAWA Akiko, OTA Masaho, KATAGIRI SATOSHI, MAEDA Shinsuke, HOSODA Kei
Authorship 2nd author,Corresponding author
Publication date 2024/01
Summary BACKGROUND/AIM:This study aimed to evaluate the long-term survival outcomes from our previous study: a phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for cT4 or N2-3 advanced gastric cancer.PATIENTS AND METHODS:The patients with clinical T4 and/or N2 or more lymph nodes received two cycles (3 weeks per cycle) of neoadjuvant chemotherapy with S-1 plus oxaliplatin (oxaliplatin at 130 mg/m2 on day 1 and S-1 at 80-120 mg/day on days 1 to 14), followed by gastrectomy with D2 lymphadenectomy. The final preplanned analysis of long-term outcomes, including overall and relapse-free survival, was performed. This trial has been completed and registered with the University Hospital Medical Information Network Clinical Trials Registry under number UMIN 000024656.RESULTS:Between May 2016 and March 2019, 30 patients were enrolled. All patients completed the protocol. After a median follow-up of 50 months for surviving patients, the 3-year overall and recurrence-free survival rates were 80.0% and 76.7%, respectively, at the last follow-up in March 2023, whereas the 5-year overall and recurrence-free survival rates were 72.7% and 73.0%, respectively.CONCLUSION:The administration of two cycles of neoadjuvant chemotherapy with S-1 plus oxaliplatin, followed by D2 gastrectomy, was associated with relatively good long-term oncologic outcomes for patients with high-risk gastric cancer.
DOI 10.21873/anticanres.16802
PMID 38160004